BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35636434)

  • 1. Melatonin Increases the Sensitivity of Osteosarcoma Cells to Chemotherapy Drug Cisplatin.
    Hosseini F; Shanehbandi D; Soleimanpour J; Yousefi B; Alemi F
    Drug Res (Stuttg); 2022 Jul; 72(6):312-318. PubMed ID: 35636434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quercetin and Methotrexate in Combination have Anticancer Activity in Osteosarcoma Cells and Repress Oncogenic MicroRNA-223.
    Mohammadi E; Alemi F; Maleki M; Malakoti F; Farsad-Akhtar N; Yousefi B
    Drug Res (Stuttg); 2022 Apr; 72(4):226-233. PubMed ID: 35385884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p.
    Cheng FH; Zhao ZS; Liu WD
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7256-7265. PubMed ID: 31539112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.
    Zhou X; Natino D; Zhai X; Gao Z; He X
    Mol Med Rep; 2018 May; 17(5):7209-7217. PubMed ID: 29568877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
    Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis.
    Yang D; Xu T; Fan L; Liu K; Li G
    J Exp Clin Cancer Res; 2020 Sep; 39(1):201. PubMed ID: 32972441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.
    Zhao G; Cai C; Yang T; Qiu X; Liao B; Li W; Ji Z; Zhao J; Zhao H; Guo M; Ma Q; Xiao C; Fan Q; Ma B
    PLoS One; 2013; 8(1):e53906. PubMed ID: 23372675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
    Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
    J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
    Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
    Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of the oncogene lncRNA NEAT1 restores the availability of
    Hu Y; Yang Q; Wang L; Wang S; Sun F; Xu D; Jiang J
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29654165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of MSH6 gene silencing in combination with cisplatin on cell proliferation of human osteosarcoma cell line MG63.
    Liu HC; Zeng J; Zhang B; Liu XQ; Dai M
    J Cell Physiol; 2019 Jun; 234(6):9358-9369. PubMed ID: 30456894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of beclin1 affects the chemotherapeutic sensitivity of osteosarcoma.
    Wu W; Li W; Zhou Y; Zhang C
    Int J Clin Exp Pathol; 2014; 7(10):7114-22. PubMed ID: 25400807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
    Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
    Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin Augments Cisplatin-Induced Apoptosis, DNA Damage Response, and MiR-22 Expression While It Prevents DNA Repair in Osteosarcoma Cells.
    Malakoti F; Majidinia M; Ahmadi Y; Yousefi B; Shanebandi D
    Drug Res (Stuttg); 2022 Sep; 72(7):378-384. PubMed ID: 35724673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinone I restrains osteosarcoma progression by regulating circ_0000376/miR-432-5p/BCL2 axis.
    Ye B; Qiao K; Zhao Q; Jiang Z; Hu N; Wang F
    Mol Cell Biochem; 2022 Jan; 477(1):1-13. PubMed ID: 34532813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
    Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-375 targeting autophagy-related 2B (ATG2B) suppresses autophagy and tumorigenesis in cisplatin-resistant osteosarcoma cells.
    Gao S; Wang K; Wang X
    Neoplasma; 2020 Jul; 67(4):724-734. PubMed ID: 32726125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of miR-181b, CYLD, CBX-7, BCL2, and p53 in osteosarcoma patients and correlation with clinicopathological factors.
    Fazli J; Fattah K; Moliani A; Valizadeh A; Bazavar M
    Chem Biol Drug Des; 2023 Jan; 101(1):2-8. PubMed ID: 36098711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.